Compositions, methods and kits relating to anti-platelet autoantibodies and inhibitors thereof
View Patent ↗The present invention relates to novel methods of identifying and producing an anti-platelet autoantibody. More preferably, the invention relates to identification and production of a human monoclonal anti-platelet autoantibody. Moreover, the invention relates to methods for treating or alleviating a disease, disorder or condition mediated by an anti-platelet autoantibody specifically binding with a platelet, or a component thereof, such as, but not limited to, idiopathic thrombocytopenic purpura, among others. Preferably, the antibody is an unglycosylated H44L4 Fab.
1. A method for inhibiting blood clotting in vivo, said method comprising administering to a human patient an effective amount of an antibody that inhibits platelet function in vivo, thereby inhibiting blood clotting in vivo, wherein said antibody is an unglycosylated H44L4 Fab [SEQ ID NO:64 (H44) and SEQ ID NO:70 (L4)].
2. A method of contacting an antibody with a glycoprotein IIb/IIIa on a platelet in vivo, comprising administering an effective amount of an antibody to a human patient, wherein said antibody is an unglycosylated H44L4 Fab [SEQ ID NO:64 (H44) and SEQ ID NO:70 (L4)], further wherein when said antibody is bound to said glycoprotein IIb/IIIa on a platelet, platelet function is inhibited.